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ApoptosisASPP2 is an important tumor suppressor protein promoting p53-dependent and-independent
apoptosis. However, it has been unclear how ASPP2 protein is regulated. Here, we identiﬁed Itch
as the E3 ubiquitin ligase for ASPP2. Itch interacts with ASPP2 and mediates its degradation and
ubiquitination in vivo. The PPXY motif of ASPP2 interacts with the WW domains of Itch. Yap1
competes with Itch for binding to ASPP2, and prevents Itch-mediated degradation and ubiquitina-
tion of ASPP2. Together, these observations reveal that Itch and Yap1 have antagonistic roles in the
regulation of ASPP2 protein stability through competing post-translational regulatory mechanism
of ASPP2.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Protein ubiquitination has emerged as a fundamental mecha-
nism for regulating the half-lives and activity of many cellular pro-
teins. The speciﬁcity of ubiquitination reactions is achieved by the
E3 ubiquitin ligases (E3’s), which mediate the transfer of ubiquitin
from E2 ubiquitin-conjugating enzymes (E2) to substrates [1].
Ubiquitination controls turnover and abundance of proteins by
targeting them for proteasomal degradation. The Nedd4-like
family contains nine members in human including Nedd4,
Nedd4-2, Itch, Smurf1, Smurf1, WWP1, WWP2, NedL1, and NedL2.
These E3 ubiquitin ligases are characterized by a distinct modular
domain architecture, with each member consisting of a Ca+2/lipid-
binding (C2) domain involved in membrane targeting, 2–4 WW
domains conferring substrate speciﬁcity, and a HECT domain
required for catalytic activities [2,3]. This family of E3 ubiquitin
ligases has been shown to regulate diverse biological processesthrough targeted degradation of proteins that generally have one
or more PPXY motifs for WW domain recognition [3]. Since the
WW domains of Nedd4-like family of E3 ubiquitin ligases have
similar binding afﬁnities, albeit to different degrees, for the PPXY
motif-containing substrates, these substrates can be degraded by
one or more Nedd4-like E3 ubiquitin ligases at different cellular
contexts. To date, a large number of PPXY motif-containing pro-
teins have been identiﬁed to be ubiquitinated and degraded by
the Nedd4-like E3 ubiquitin ligases.
ASPP2 is one of the three members of the ASPP (Apoptosis
Stimulating Proteins of p53) family, which also includes ASPP1
and iASPP [4]. ASPP2 interacts with p53 and speciﬁcally enhances
p53-induced apoptosis but not cell cycle arrest [5]. ASPP2 has also
been shown to be an important tumor suppressor, and its expres-
sion is dramatically reduced in various types of human tumors [6].
Importantly, targeting of the ASPP2 allele in two different mouse
models reveals that ASPP2 heterozygous mice are prone to sponta-
neous and c-irradiation–induced tumors, which rigorously estab-
lished BAP1 as a bona ﬁde tumor suppressor [6,7]. In addition
p53 pathway, ASPP2 regulates epithelial cell polarity through
interaction with the PAR complex [8,9]. ASPP2 also cooperates with
PP1 to dephosphorylate and activate TAZ, a transcriptional factor of
Hippo pathway [10]. Despite its importance in diverse cellular
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ﬁned. ASPP2 protein has been found to be ubiquitinated and
degraded through ubiquitin–proteasome pathway [11]. A recent
study reported that E3 ubiquitin ligase Siah2 can targets ASPP2
for ubiquitination and degradation under hypoxia [12].
Herein,we demonstrated that Itch directly interactswith and act
as a robust E3 ubiquitin ligases for ASPP2. Yap1 competed with Itch
for binding to ASPP2, and prevented Itch-mediated degradation and
ubiquitination of ASPP2. Thus, these results revealed that Itch and
Yap1 play antagonistic roles in regulating ASPP2 protein stability.
2. Materials and methods
2.1. Cell culture and transfection
293T and H1299 cells were obtained from the American Type
Culture Collection (ATCC). 293T cells were maintained in DMEM
with 10% FBS. H1299 cells were maintained in RPMI 1640 with
10% FBS. Cells were transfected using Lipofectamine 2000 (Invitro-
gen) according to manufacturer’s instructions.
2.2. Expression constructs
The ASPP2 cDNA was provided by Dr. Xin Lu (University of
Oxford, UK.) and subcloned into pCMV-HA vector. WT and CA
(catalytically inactive) mutant of Itch were provided by Dr. Gerry
Melino (Leicester University, UK.). Nedd4 and Nedd4-2 constructs
were provided by Dr. Christie P. Thomas (University of Iowa,
U.S.A.). Myc-Smurf1/2 and Myc-WWP1 were provided by Dr. Kohei
Miyazono (University of Tokyo, Japan). Myc-WWP2 constructs
were provided by Dr. Ying Jin (Chinese Academy of Sciences,
China). WT or WW⁄ mutant of Yap1 constructs were provided by
Dr. Marius Sudol (Weis Center for Research, U.S.A.). Myc-p53 con-
structs were provided by Dr. Wei Gu (Columbia University, U.S.A.).
All ASPP2- or Itch-deletion mutants were generated using the
KOD-Plus Mutagenesis Kit (Toyobo, Japan).
2.3. RNA interference
The RNAi oligos were purchased from Genepharma (Shanghai,
China). The RNAi oligos sequences for Itch are: RNAi #1: 50-CCAGU
UGGACUCAAGGAUUUAdTdT-30; RNAi #2: 50-GGUGACAAAGAGCCA
ACAGAGdTdT-30. The RNAi oligos sequences for ASPP2 are: 50-AAG
UUGCUGAGCAGGAGAAAdTdT-30. The RNAi oligos sequences for
Yap1 are: 50-CCAGAGAAUCAGTCAGAGA dTdT-30. The sequence of
negative control is: 50-ACAGACUUCGGAGUACCUGdTdT-30.
2.4. Antibodies
For Western blotting, the following antibodies were used:
ASPP2 (611354; BD Biosciences), Itch (sc-28367; Santa Cruz),
Yap1 (sc-15407; Santa Cruz), Myc (9E10; Sigma), Myc(562: MBL),
Flag (M2; Sigma), HA (MM5-101R; Millipore), GFP (sc-8334; Santa
Cruz), Actin (AC-74 ; Sigma).
2.5. Transcriptional reporter assay
Luciferase assay (Promega) was conducted in cells that were
transiently transfected with the reporter constructs (p53-Luc),
pTK-galactosidase construct and the ASPP2/Itch plasmids or
siRNAs. Luciferase activity in cell lysates was measured using the
luciferase assay system in a Berthold Lumat LB 9507 luminometer
(Promega). Luciferase activity was normalized to galactosidase
activity as an internal control. Each assay was performed intriplicate and results were conﬁrmed by at least three individually
repeating experiments.
2.6. Immunoprecipitation
Cells were lysed with cell lysis buffer (20 mM Tris–HCl, pH 7.5,
150 mM NaCl, 1% Triton, 1 mM EGTA, 1 mM Na2EDTA, 2.5 mM
sodium pyrophosphate, 1 mM b-glycerophosphate, 1 mM Na3VO4
and 1 lg/ml leupeptin) and the lysate was centrifuged (12000g
for 20 min). The supernatant was precleared with protein A/G
beads (Sigma, USA), followed by incubation with 2 ll antibodies
for 2 h and thereafter with protein A/G beads for 2 h, all at 4 C.
Pellets were washed 4 times with lysis buffer and resuspended in
sample buffer and analyzed by SDS–PAGE.
2.7. Western blotting
Cell lysates and immunoprecipitates were subjected to SDS–
PAGE and proteins were transferred to nitrocellulose membranes
(GE Healthcare). The membrane was blocked in PBS containing
5% non-fat milk and 0.1% Tween-20, washed twice in PBS, and
incubated with primary antibody at room temperature for 2 h,
followed by incubation with secondary antibody at room temper-
ature for 45 min. Afterward, the proteins of interest were visual-
ized using ECL chemiluminescence system (Santa Cruz).
2.8. Immunoﬂuorescence
H1299 cells cultured on coverslips were ﬁxed in 4% paraformal-
dehyde for 10 min and permeabilized in 0.2% Triton X-100 for
5 min at room temperature. The coverslips were blocked with 5%
normal goat serum plus 2% BSA for 1 h and then incubated with
anti-HA and anti-Myc antibodies for 1 h at room temperature,
which was followed by sequential incubation with a Alexa-
conjugated anti-Mouse/rabbit second antibodies for 30 min at
room temperature. Finally, cells were counterstained with DAPI
to reveal the nuclei. Epiﬂuorescence images were captured using
Leica confocal Microscope (Japan).
2.9. GST-pulldown assay
293T cells were lysed 36 h after transfection with 1 cell lysis
buffer at 4 C. GST fusion proteins were immobilized on glutathi-
one-Sepharose beads (Amersham Biosciences). After washing with
pull-down buffer (20 mM Tris–HCl, pH 7.5, 150 mM NaCl, 0.1%
NP-40, 1 mM DTT, 10% glycerol, 1 mM EDTA, 2.5 mM MgCl2 and
1 lg/ml leupeptin), the beads were incubated with lysates of
293T cells or Escherichia coli expressed and puriﬁed recombinant
proteins for 2 h. The beads were then washed 5 times with binding
buffer and resuspended in sample buffer. The bound proteins were
subjected to SDS–PAGE.
2.10. Quantitative RT-PCR
Total RNA was isolated from H1299 cells using the TRIzol
reagent (Tiangen, China), and cDNA was reversed-transcribed
using the Superscript RT kit (TOYOBO, Japan), according to the
manufacturer’s instructions. PCR primer sequences for human
ASPP2 were selected as follows: 50-GAAGACTCGGTGAGCATGC
G-30 (forward) and 50-CAGAGGTCAGAGAAGAAGTAGG-30 (reverse).
Human Itch primer sequences are as follows: 50-CAAGACCTTCACG
ACCACCAC-30 (forward) and TCCAGATGTTGCTCCTTCAGATG-30
(reverse). PCR ampliﬁcation was performed using the SYBR Green
PCR master mix Kit (TOYOBO, Japan). All quantitations were nor-
malized to the level of endogenous control GAPDH.
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3.1. ASPP2. forms a complex with Itch
In an attempt to elucidate the novel regulatory mechanism of
ASPP2, we established a H1299 derivative cell line that stably
expressing Flag-HA double tagged-ASPP2. Tandem afﬁnity puriﬁ-
cation (TAP) followed by mass spectrometry analysis allowed us
to discover several ASPP2 interacting proteins (Table S1). In addi-
tion to known ASPP2 interactors, such as Par-3, Yap1 and PP1 sub-
units (PP1a, b, c), we identiﬁed the E3 ubiquitin ligase Itch, as a
potential new binding partner of ASPP2. At ﬁrst, we wanted to con-
ﬁrm whether the interaction exists between these two proteins. To
this end, we co-expressed HA-ASPP2 and Myc-Itch in 293T cells
and immunoprecipitated Myc-Itch. As shown in Fig. 1A, HA-ASPP2
was co-immunoprecipitated with Myc-Itch. Similar results were
obtained in a reciprocal co-immunoprecipitation experiment using
anti-HA antibody (Fig. 1A). Next, we extended our analysis by
investigating whether endogenous ASPP2 and Itch can interact
with each other. When endogenous Itch in H1299 cells was immu-
noprecipitated by anti-Itch antibody, ASPP2 was detectable in the
immunoprecipitates by Western blotting (Fig. 1B, left panel). More-
over, a reciprocal immunoprecipitation experiment was performed
in which endogenous ASPP2 was immunoprecipitated. Itch was
also detectable in the immunoprecipitates (Fig. 1B, right panel).
To further verify the interaction between ASPP2 and Itch, we
examined whether these two proteins are localized to the same
subcellular compartments. The subcellular localizations of co-
overexpressed ASPP2 and Itch were monitored by immunoﬂuores-
cence using Myc/HA antibodies. As shown in Fig. 1C, FH-ASPP2 and
Myc-Itch were co-localized in the cytoplasm. Taken together, these
results indicated that ASPP2 forms a complex with Itch in vivo.
3.2. Itch regulates ASPP2 turnover in vivo
We determined whether one or more member of Nedd4-like
ubiquitin E3 ligases might mediate ASPP2 degradation. HA-ASPP2
was co-expressed with a panel of Nedd4-like family of E3 ubiquitin
ligases, including Nedd4, Nedd4-2, Smurf1, Smurf2, Itch, WWP1,
and WWP2 in 293T cells. As shown in Fig. 2A, of all E3 ubiquitin
ligases tested, only Itch efﬁciently promoted ASPP2 degradationFig. 1. ASPP2 forms a complex with Itch. (A) 293T cells were co-transfected with H
immunoprecipitation with anti-HA or anti-Myc antibodies and WB analyses. (B) Endog
H1299 cell lysates were incubated with protein A/G Sepharose conjugated with either
followed by Western blotting with indicated antibodies. Right panel, similar assay was p
subcellular co-localization of overexpressed FH-ASPP2 and Myc-Itch were detected by iin a dose-dependent manner. Moreover, we found that ASPP2
degradation induced by Itch co-expression could be signiﬁcantly
rescued by the proteasome inhibitor MG132 or lactacystin,
suggesting Itch downregulates ASSP2 protein via the proteasomal
degradation pathway (Fig. 2B). To verify the roles of Itch in ASPP2
degradation, we tested E3 ubiquitin ligase mutants in which the
highly conserved Cys residue in its HECT domain was mutated to
Ala. The Cys to Ala mutation has been shown to abrogate ubiquitin
ligase activities. As shown in Fig. 2C, Itch-WT, but not the CA
mutant, promoted ASPP2 degradation in a dose-dependent
manner, indicating that the HECT domain and its ubiquitin ligase
activity of Itch is required for promoting ASPP2 degradation. Next,
we determined the effects of Itch on ASPP2 protein turnover. 293T
cells were co-transfected with HA-ASPP2 expression construct,
empty vector, and Itch (WT or CA) mutant. After 24 h, cells were
treated with cycloheximide (CHX). As shown in Fig. 2D and E,
co-expression of Itch-WT accelerated ASPP2 protein turnover
when compared with ASPP2 expression alone. In contrast, ASPP2
was stabilized by the Itch-CA mutant, likely due to a dominant
negative effect of the catalytically inactive mutant on the wild type
enzyme (Fig. 2D and E). Given that Itch is an E3 ubiquitin ligase,
and induced ASPP2 degradation upon co-expression, it is
reasonable that ASPP2 is an ubiquitination substrate of Itch. To
assess this possibility, we co-expressed HA-ASPP2, Ubiquitin and
Myc-Itch-WT, or Itch-CA mutant in 293T cells. The polyubiquiti-
nated forms of ASPP2 were immunoprecipitated and then detected
by Western blotting. As shown in Fig. 2F, ASPP2 was robustly poly-
ubiquitinated by co-expression of Itch-WT in a dose-dependent
manner. In contrast, little or no ASPP2 polyubiquitination was
observed in Itch-CA mutant expression cells.
Next, we determined whether Itch affects the protein level of
endogenous ASPP2. We knocked down the endogenous Itch by
two speciﬁc siRNAs and determined the changes in ASPP2 protein
level in H1299 cells. As shown in Fig. 2G, knockdown of Itch in
H1299 cells resulted in a marked increase in the level of endoge-
nous ASPP2. To exclude the possibility that ASPP2 protein elevation
resulted from transcriptional up-regulation, we performed qRT-
PCR to measure the mRNA levels of ASPP2 and Itch in Itch-depleted
H1299 cells. In contrast to the signiﬁcant decrease in mRNA level
of Itch, the mRNA level of ASPP2 in Itch-depleted H1299 cells
stayed at a level similar to that of control cells (Fig. 2H). Moreover,A-ASPP2 and Myc-Itch constructs. After 24 h, cell lysates were prepared for co-
enous Itch and ASPP2 proteins interact with each other in H1299 cells. Left panel,
control IgG or Itch antibody. The immunoprecipitates were resolved on SDS–PAGE
erformed as left panel but immunoprecipitated using anti-ASPP2 antibody. (C) The
mmunoﬂuorescence. Nuclei were stained with DAPI.
Fig. 2. Itch regulates ASPP2 turnover in vivo. (A) HA-ASPP2 and increasing amounts of Nedd4-like E3 ubiquitin ligases (Nedd4, Nedd4-2, Itch, Smurf1, Smurf2, WWP1, and
WWP2) constructs were transfected in 293T cells. After 24 h, cell lysates were prepared for WB analyses. The pEGFP–N3 constructs were included as a transfection efﬁciency
control. (B) HA-ASPP2 and increasing amounts of Myc-Itch constructs were transfected in 293T cells. After 24 h, cells were treated with of the proteasome inhibitor MG132
(20 lM), lactacystin (10 lM) or DMSO for 6 h before cell lysates were prepared for WB analyses. (C) HA-ASPP2 and increasing amounts of Myc-Itch (WT or CA mutant)
constructs were transfected in 293T cells. After 24 h, cell lysates were prepared for WB analyses. (D and E) 293T cells were co-transfected with HA-ASPP2, along with empty
vector, Myc-Itch (WT or CA mutant) constructs. After 24 h, cells were treated with 50 lg/ll cycloheximide (CHX). At various time points cells were harvested for WB analyses
(D). At each time point, the intensity of ASPP2 was normalized to the intensity of actin ﬁrst and then to the value at the 0-h time point (E). The mean values (S.D.) of three
independent experiments are shown. (F) HA-ASPP2, pcDNA.3-Ubiquitin and Myc-Itch, or CA mutant constructs were co-transfected in 293T cells. After 24 h, cells were
treated with 20 lM MG132 for 6 h. ASPP2 proteins were immunoprecipitated by anti-HA antibody. The immunoprecipitates were resolved on SDS–PAGE followed by
Western blotting with indicated antibodies. (G) H1299 cells were transfected with control siRNA or two siRNAs for Itch. After 48 h, cell lysates were prepared for WB analyses
with indicated antibodies. (H) qRT-PCR measurement of the mRNA levels of ASPP2 and Itch in Itch-depleted H1299 cells. The mRNA level of GAPDH was used for
normalization. The mean values (S.D.) of three independent experiments are shown.
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half-life of endogenous ASPP2 (Fig. S1A and B). Taken together,
these results supported the notion that the E3 ubiquitin ligase Itch
regulates ASPP2 stability through the ubiquitin-dependent prote-
asomal degradation pathway.
3.3. Itch suppresses ASPP2-mediated p53 transactivation and
apoptosis
ASPP2 has been shown to promote p53-mediated apoptosis by
speciﬁcally enhancing its ability to induce the transcription of
proapoptotic genes [5]. We examined whether Itch affects
ASPP2-mediated p53 transactivation by Luciferase reporter assay.
As previously shown, ASPP2 was able to increase the p53-lucifer-
ase reporter activity in a p53-dependent manner (Fig. 3A). How-
ever, this effect can be reversed by co-expression of Itch-WT. In
contrast, Itch-CA mutant failed to inhibit p53 reporter activity
under the same conditions (Fig. 3A). Next, we examined whether
knockdown of endogenous Itch affects ASPP2-mediated p53 trans-
activation. H1299 cells was transfected with Itch or/and ASPP2 siR-
NAs, after 24 h, the cells were transfected with Myc-p53 and p53
luciferase reporter constructs. As shown in Fig. 3B, knockdown of
ASPP2 by siRNAs decreased p53 reporter activity. By contrast,
knockdown of Itch by siRNAs moderately increases p53 reporter
activity. More importantly, knockdown of both ASPP2 and Itch
decreased p53 reporter activity similar as knockdown of ASPP2
only. This result suggested Itch can modulate p53 transactivation,
at least in part, through regulating ASPP2 stability.
Consistent with the results of p53 reporter assay, we found that
ASPP2 was able to increase p53-mediated apoptosis in H1299 cells
(Fig. 3C). Itch-WT, but not the Itch-CA mutant, suppresses ASPP2-
mediated enhancement of p53-dependent apoptosis under the
same conditions (Fig. 3C). Taken together, these results suggestedFig. 3. Itch suppresses ASPP2-mediated p53 transactivation and apoptosis. (A) H1299 cel
activities were measured by luminometer. Below: WB analyses of protein expression
transfected with Itch or/and ASPP2 siRNAs. After 48 h, the cells were transfected with M
reporter activities were measured by luminometer. Below: WB analyses of protein expre
cells were transfected with indicated constructs. After 36 h, the apoptotic cells were
experiments are shown.that the E3 ubiquitin ligase Itch indirectly regulated p53-mediated
transactivation and apoptosis in an ASPP2-dependent manner.
3.4. Binding of Itch to ASPP2 is mediated through the WW domain of
Itch and the PPXY motif of ASPP2
Human ASPP2 protein possesses a PPXY motif which is highly
conserved across a wide range of metazoans (Fig. 4A and B). More-
over, this motif is not present in ASPP1 and iASPP, two paralogs of
ASPP2 (Fig. 4A). Itch contains multiple WW domains at its central
region (Fig. 4C). We investigated whether the ASPP2-Itch interac-
tion is mediated through these domains. First, we generated four
truncation mutants of ASPP2 (D1–D4). These mutants were fused
to GST, expressed and puriﬁed from bacteria. A GST pull-down
assay was then performed with GST fusion proteins of ASPP2
(D1–D4) and Myc-Itch over-expressed in 293T cells. As shown in
Fig. 4D, the ASPP2-D3 harboring PPXY motif, but not the D1, D2
or D4 mutant, speciﬁcally interacted with Myc-Itch. Moreover,
deletion of the PPXY motif totally abolished the interaction
between ASPP2-D3 and Myc-Itch (Fig. 4D), suggesting the PPXY
motif in ASPP2 is indispensable for Itch binding. Moreover, pull-
down assay showed GST-Itch can pull down recombinant
expressed His-ASPP-D3, but His-ASPP2-D3 DPY proteins (Fig. S2),
suggesting ASPP2 can directly interact with Itch in vitro in a PPXY
motif-dependent manner.
Next, we generated three deletion mutants of Itch and deter-
mined the minimal region that is sufﬁcient to mediate its interac-
tion with ASPP2. Thus Wild type (WT) and three of Itch-deletion
mutants containing the C2 domain (C2), WW domain (WW), HECT
domain (HECT), were fused to GST and expressed in and puriﬁed
from bacteria. A GST pull-down assay for Itch and HA-ASPP2
expressed in 293T cells was carried out. As shown in Fig. 4E,
Itch-WW, but not the C2 or HECT mutant interacted with ASPP2.ls were transfected with indicated constructs. After 24 h, the p53 luciferase reporter
in H1299 cells transfected with the indicated constructs. (B) H1299 cells were
yc-p53 and p53 luciferase reporter constructs for another 24 h. The p53 luciferase
ssion in H1299 cells transfected with the indicated constructs or siRNAs. (C) H1299
measured using PI staining assay. The mean values (S.D.) of three independent
Fig. 4. Itch and ASPP2 interact with each other through the WW domains and PPXY motif. (A) Protein sequence alignment of ASPP2 orthologues from the different species.
The protein sequences of ASPP1 and iASPP are also included. The conserved PPXY motif was boxed. (B and C) Various deletion mutant constructs of ASPP2 (B) and Itch (C) are
shown schematically. (D) Bacterially expressed GST fusion proteins of ASPP2 deletion mutants were bound to glutathione-Sepharose beads as indicated and incubated with
cell lysates of 293T cells transfected with Myc-Itch. Bound Myc-Itch was subjected to WB analyses with anti-Myc antibody. The GST fusion proteins of ASPP2 deletion
mutants were detected by ponceau S staining. (E) Bacterially expressed GST fusion proteins of wild type (WT), C2 domain (C2), WW domain (WW), HECT domain (HECT)
mutants of Itch were bound to glutathione-Sepharose beads and incubated with cell lysates of 293T cells transfected with the HA-ASPP2. Bound HA-ASPP2 was subjected to
WB analyses with anti-HA antibody. The GST fusion proteins of Itch or deletion mutants were detected by ponceau S staining. (F) Various deletion mutation constructs of
ASPP2 are shown schematically. (G) 293T cells were transfected with HA-ASPP2-WT or deletion mutants and increasing amounts of Myc-Itch. After 24 h, cell lysates were
prepared for WB analyses.
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Next, we determined whether the PPXY motif was also essential
for Itch-mediated ASPP2 degradation. We generated three
C-terminal deletion mutants (ASPP2-C1, C2 and C3) and a PPXY
deletion mutant (ASPP2-DPY) (Fig. 4F). As shown in Fig. 4G, Itch
targeted full length ASPP2 or mutants harboring PPXY motif
(ASPP2-C1, C2) for degradation, whereas deletion of the C-terminal
part harboring PPXY motif (ASPP2-C3) or PPXY motif (ASPP2-DPY)
caused totally resistant to Itch-mediated ASPP2 degradation. Takentogether, these results indicated that the PPXY motif was required
for ASPP2-Itch interaction and ASPP2 degradation.
3.5. Yap1. stabilizes ASPP2 by preventing Itch-mediated degradation
and ubiquitination of ASPP2
ASPP2 has also been reported to interact with the transcrip-
tional factor Yap1 [13]. Yap1 binds to ASPP2 through its PPXYmotif
and the WW domain of ASPP2 [13]. Given the fact that both Yap1
and Itch bind the same PPXY motif of ASPP2, it appeared possible
100 K. Gao et al. / FEBS Letters 589 (2015) 94–101that upon Yap1 binding to the PPPY motif, this motif is sequestered
to prevent access to Itch. To test this possibility, we transfected
HA-ASPP2 alone or in combination with increasing amounts of
Yap1-WT or WW⁄ mutant constructs in 293T cells. As shown in
Fig. 5A, co-expression of ASPP2 with increasing amounts of Yap1
gave rise to an increase in the steady-state levels of ASPP2. How-
ever, Yap1-WW⁄ mutant overexpression cannot lead to ASPP2
accumulation. It is not surprising, since the Yap1-WW⁄ mutant in
which the second conserved tryptophan and the conserved proline
of the WW domain were each substituted to alanine, lost its ability
to binding to the PPXY motif of ASPP2 [13]. Next, we examined theFig. 5. Yap1 stabilizes ASPP2 by preventing Itch-mediated degradation and ubiquitination
constructs were transfected in 293T cells. After 24 h, cell lysates were prepared for WB
cells. After 24 h, cell lysates were prepared for WB analyses. (C) HA-ASPP2 (WT or DPY
cells. After 24 h, cell lysates were prepared for WB analyses. (D) 293T cells were transfect
another 6 h before cell lysates were prepared for co-IP with anti-HA antibody and WB a
were transfected control or a Yap1-speciﬁc siRNA. At 36 h, cell lysates were prepared fo
antibodies. (F) 293T cells were transfected with HA-ASPP2, Myc-Itch and Flag–Yap1 (WT
WB analyses. (G) 293T cells were transfected with indicated constructs. After 24 h, celleffect of Yap1 on the protein level of endogenous ASPP2. As shown
in Fig. 5B, overexpression of Yap1 in 293T cells stabilized
endogenous ASPP2 in a dose-dependent manner. Moreover,
ASPP2-DPY mutant failed to accumulate in response to Yap1 over-
expression (Fig. 5C), suggesting the physical interaction between
ASPP2-Yap1 is critical for ASPP2 stabilization. Since Itch and
Yap1 bind to the same ASPP2 PPXY motif, we predicted that
Yap1 stabilizes ASPP2 by competing with Itch for the binding to
ASPP2. As shown in Fig. 5D, in the absence of Yap1, Itch was
co-immunoprecipitated with ASPP2, however, the level of
ASPP2-associated Itch was decreased in the presence of Yap1, inof ASPP2. (A) HA-ASPP2 and increasing amounts of Flag-Yap1 (WT or WW⁄ mutant)
analyses. (B) Increasing amounts of Flag-Yap1 constructs were transfected in 293T
mutant) and increasing amounts of Flag-Yap1 constructs were transfected in 293T
ed with indicated constructs. After 24 h, cells were treated with MG132 (20 lM) for
nalyses. (E) Ablation of Yap1 may enhance the ASPP2–Itch interaction. H1299 cells
r immunoprecipitation with anti-ASPP2 antibody and WB analyses with indicated
or WW⁄ mutant) constructs as indicated. After 24 h, cell lysates were prepared for
lysates were prepared for co-IP with anti-HA antibody and WB analyses.
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nous YAP in H1299 cells markedly increased the endogenous
ASPP2-Itch interaction (Fig. 5E). We also found that Yap1 but not
the Yap1-WW⁄ mutant overexpression reversed Itch-mediated
ASPP2 degradation (Fig. 5F). Finally, we demonstrated that
Itch-mediated ASPP2 ubiquitination was dramatically decreased
by Yap1 in a dose-dependent manner (Fig. 5G).
4. Discussion
In this study, we unraveled a post-translational regulatory
mechanism of ASPP2 protein stability in cells. Among three lines
of experimental evidences are: (1) endogenous ASPP2 interacts
with Itch, and the interaction was mediated through the PPXY
motif of ASPP2 and the WW domain of Itch; (2) Itch destabilizes
ASPP2 by targeting it for ubiquitin-dependent proteasomal degra-
dation; (3) Yap1 stabilizes ASPP2 by preventing Itch-mediated deg-
radation and ubiquitination of ASPP2. This process requires the
interaction between the PPXY motif of ASPP2 and the WW domain
of Yap1. Thus, our ﬁnding suggested that the PPXY motif in ASPP2
is important for the control of protein fate of its own.
Previous study reported that proteasomal degradation modu-
lates ASPP2 protein levels and apoptotic function. Treatments of
cells with proteasome inhibitors, including the clinically utilized
bortezomib, dramatically stabilize endogenous ASPP2 proteins
[11]. Importantly, chemotherapy drug doxorubicin treatment in
HT1080 cells led to a profound increase in ASPP2 protein levels,
but not the mRNA levels, suggesting that a post-transcriptional
process participates in modulating ASPP2 protein levels [11]. It is
interesting to investigate whether DNA damage signal modulates
Itch-mediated ASPP2 degradation. A recent study reported that E3
ubiquitin ligase Siah2 is a bond ﬁde ubiquitin ligase for ASPP2
[12]. Inhibition of Siah2 expression increases ASPP2 levels and
enhances ASPP2-dependent maintenance of tight junction integrity
[12]. How ASPP2 protein stability is regulated by different E3
ubiquitin ligases under environmental stresses has yet to be
determined.
In addition to ASPP2, Yap1 also binds to proapoptotic factor p73
through its WW domain and the PPPY motif of p73 to serve as a
p73 transcription coactivator [14]. In addition, Yap1-p73 interac-
tion protects p73 from proteasomal degradation by preventing
the association of p73 with the E3 ubiquitin ligase Itch, which also
binds to p73 via a WW domain [15]. Previous study showed that
Yap1 was required for cisplatin-induced apoptosis in H1299 cells
[16]. Yap1 was phosphorylated by c-Abl kinase in response to
DNA damage. Tyrosine-phosphorylated Yap1 is a more stable
protein that displays higher afﬁnity to p73 and selectively coacti-
vates p73 proapoptotic target genes [16]. Since ASPP2 stimulates
the pro-apoptotic activities of p53 and its family members, p63
and p73 [4], it appeared possible that Yap1 stabilizes multiplePPXY-containing factors, including ASPP2 and p73, to trigger
apoptosis in DNA damage response.
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